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Abstract: Metabolomics based on untargeted flow infusion electrospray ionization high-resolution
mass spectrometry (FIE-HRMS) can provide a snap-shot of metabolism in living cells. Lung Squamous
Cell Carcinoma (SCC) is one of the predominant subtypes of Non-Small Cell Lung Cancers (NSCLCs),
which usually shows a poor prognosis. We analysed lung SCC samples and matched histologically
normal lung tissues from eight patients. Metabolites were profiled by FIE-HRMS and assessed
using t-test and principal component analysis (PCA). Differentially accumulating metabolites were
mapped to pathways using the mummichog algorithm in R, and biologically meaningful patterns
were indicated by Metabolite Set Enrichment Analysis (MSEA). We identified metabolic rewiring
networks, including the suppression of the oxidative pentose pathway and found that the normal
tricarboxylic acid (TCA) cycle were decoupled from increases in glycolysis and glutamine reductive
carboxylation. Well-established associated effects on nucleotide, amino acid and thiol metabolism
were also seen. Novel aspects in SCC tissue were increased in Vitamin B complex cofactors, serotonin
and a reduction of γ-aminobutyric acid (GABA). Our results show the value of FIE-HRMS as a high
throughput screening method that could be exploited in clinical contexts.
Keywords: lung squamous cell carcinoma; flow infusion electrospray ionization high resolution
mass spectrometry; untargeted metabolites; pathways
1. Introduction
The Global Cancer Statistics 2018 (based on GLOBOCAN 2018 estimates) indicate that lung cancer
remains the leading cause of cancer incidence and mortality for 2018, with 2.1 million new cases and
1.8 million deaths [1]. Lung cancer can be classified into two main histologic types: non-small cell
lung cancer (NSCLC, approximately 85% of the cases) or small cell lung cancer (SCLC, ~15%) [2].
NSCLC is further sub-classified into three main histological subtypes: adenocarcinoma (AD, ~40%),
squamous cell carcinoma (SCC, ~30%), large cell carcinoma (~15%) and a few others [3]. Lung SCC is
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aggressive and commonly difficult to treat, as patients tend to be older and have a higher incidence
of comorbidities compared to other NSCLC subtypes. Additionally, diagnosis tends to occur at an
advanced disease stage [4]. New strategies are needed for patients with lung SCC, especially to
understand the link between tumour behaviour and metabolism.
Metabolomics, the measurement of metabolites and metabolism as products of cellular
processes [5] can be used in high through put mode to provide a “snap-shot” of metabolism,
as represented by a biological sample [6,7]. Robust analyses pipelines have been developed for
metabolomics, so that they are emerging as an informative technique to help precision medicine
to further improve patient diagnosis and treatment [8,9]. Metabolism in lung cancer tumours is
characterised by the Warburg effect, where even in the presence of normal levels of oxygen, glycolysis
and the production of lactate is a predominant feature, even though this yields few molecules of
ATP [10]. This leads to increases in glucose and TCA cycle intermediates [11,12]. Indeed, glucose
activated proteins drive cancer proliferation [13]. Lung cancer carcinogenesis is also linked to perturbed
lipid processing via β-oxidation so that reduced cytosolic levels of the long chain fatty acid catabolite
acetylcarnithine is a marker for NSCLC [14]. The TCA cycle can be further fed by anaplerotic
reactions from the metabolism of glutamine to form α-ketoglutarate, and amino acid processing
is a feature of lung cancer. Increased glycolysis via glucose-6-phosphate also feeds into nucleotide and
therefore nucleic acid biosynthesis, which can maintain tumour cell division [15]. Cellular membrane
biosynthesis is fed by increased fatty acid production, leading to phospholipid production [16]. Thus,
extensive biochemical characterisation has successfully yielded biomarkers for the detection and
staging of lung cancers in tissue, serum, plasma and urine [17]. Our own analyses have detected
potential biomarkers in sputum, and have suggested key differences in such as polyamine and lipid
ganglioside metabolism [18].
Herein, we have analysed histologically paired normal and tissue samples from patients with lung
SCC using flow infusion electrospray ionization high resolution mass spectrometry (FIE-HRMS) as an
approach that allows rapid sample screening encompassing a wide range of metabolites. Our analyses
indicated metabolic rewiring in lung SCC tumours that were broadly similar to other metabolomic
studies of NSCLC. Some previously unreported features included changes in metabolism towards
creatine, serotonin and a range of enzyme co-factors, most particularly, of the vitamin B complex.
Our approach demonstrates the potential of FIE-HRMS in improving diagnosis and classification of
tissues, and could be useful in the development of future clinical applications to improve targeted
treatment strategies in lung SCC.
2. Materials and Methods
2.1. Patient Samples
This study was performed with the approval of the Research Ethics Board of the Faculty of
Medicine, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil. All eligible patients were
untreated before surgery and provided informed consent before sample collection. A total of 8 paired
samples (tumour tissue and matched histologically normal tissue) were collected from patients with
lung SCC. Patients were primarily treated by surgical removal of the tumour, at Clinical Hospital
of Botucatu in São Paulo state, Brazil. Primary lung SCC and histologically normal samples were
subjected to frozen section histology analysis to confirm the presence of tumour or normal cells in at
least 90% of tissues. Samples were snap-frozen in liquid nitrogen until metabolite extraction. Clinical
and histopathological data are provided in Table 1.
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Table 1. Clinical and histopathological characteristics of samples (8 patients).
Variables N
Age at diagnosis (years)
Median (range) 55 (39–71)
Gender
Male 5
Female 3
Tobacco use
Yes 7
No 1
Alcohol use
Yes 5
No 3
T category
T1-T2 6
T3-T4 2
Nodal status (pathological)
Negative (N0) 6
Positive (N1, N2) 2
Disease stage
IA 1
IIA 1
IIIA 2
IB 3
IIB 1
Tumour grade
Well differentiated 1
Moderately differentiated 5
Poorly differentiated 2
Perineural invasion
Yes 1
No 7
Angiolymphatic invasion
Yes 6
No 2
Outcome
Alive with disease 6
Death cause by disease 2
2.2. Metabolites Extraction
The solid tumour and adjacent normal tissues (~10 mg) were placed in 2 mL sterile microcentrifuge
tubes, each containing a single stainless steel ball (acetone cleaned), and were immediately flash-frozen
in liquid N2 and homogenized using a ball mill, and then placed on ice. Then, 1 mL of
chloroform:methanol:dH2O (1:2.5:1) was added. The samples were shaken at 4 ◦C degrees for 15 min
and returned to ice. Samples were centrifuged at 4 ◦C degrees at 5000× g for 3 min and dried in vacuum
to form a pellet in a microcentrifuge tube. The samples were couriered to the UK and analysed within
7d. To analyse the samples, 250 µL of 70 % methanol was added to the pellets which were resuspended
by vortexing for 5 s. For flow infusion electrospray ionization high resolution mass spectrometry
(FIE-HRMS), 100 µL of each sample was transferred into a glass vial and sealed. All samples were run
in duplicate with no significant differences in the results obtained.
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2.3. Untargeted Metabolite Fingerprinting by Flow Infusion Electrospray Ionization High Resolution Mass
Spectrometry (FIE-HRMS)
FIE-HRMS was performed using Q executive plus mass analyser instrument with UHPLC system
(Thermo Fisher Scientific©, Bremen, Germany), where m/z were generated in positive and negative
ionization mode in a single run as described by Baptista et al. [19].
2.4. Statistical Analysis
Statistical analyses were performed with MetaboAnalyst 4.0 using R and Bioconductor
packages [20]. Data filtering removed variables that were unlikely to be used when modelling the data
based on the interquantile range (IQR) [21]. The data were normalised to percentage total ion count and
then log transformed and auto scaled [22]. The univariate analyses used t-test to identify significant
m/z, p-value > 0.05. Principal component analysis (PCA) and partial least squares-discriminant analysis
(PLSDA) were used to distinguish the difference between the two sample groups. Major sources of
variation were displayed using a heatmap and unsupervised hierarchical clustering.
The matched compound and pathway identification used the mummichog algorithm within
MetaboAnalyst 4.0 from high-resolution MS peaks, without prior peak annotation. Compounds were
identified based on mass-to charge (m/z); the p-values and t-scores which were used to interrogate
the BioCyc library. Metabolite identification considered all potential matches (isotopes/adducts).
The pathway enrichment tests used Fisher’s exact tests (FET) or hypergeometric p-values [23].
The metabolite and the disease interaction networks were based on KEGG, molecular interaction
networks [24]. Metabolite Set Enrichment Analysis (MSEA) was performed to identify the biologically
meaningful patterns [25]. Significant annotated compound names, Over Representation Analysis
(ORA) and a metabolite set library were done as described [26,27].
3. Results
In this study, 16 samples were assessed using FIE/MS-based metabolomics; 8 were lung
cancer SCC tumour tissue, paired with 8 samples from the surrounding histologically normal tissue.
The derived metabolomic data were assessed using PCA and for both negative (Figure 1A) and positive
ionization mode (Figure 1B). The major sources of variation discriminate between the tumour and
histologically normal tissue. Within the cancer group (green circles), no subdivisions into stages could
be observed.
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representing TCA metabolites were extracted from the matrix, and exhibited no significant 
differences between the paired tissue (Supplementary Figure S3). A Metabolite Set Enrichment 
Analysis (MSEA) based on Over Representation Analysis (ORA) was used to display significantly 
enhanced pathways (Figure 3). These indicated lung SCC-linked rewiring metabolism in nucleotide, 
sugar, amino acid and thiol pathways. Most of our characterised metabolite changes had already 
been linked to lung cancer, as also indicated by a joint-pathway analysis (Figure 4). Key nodes linked 
to hypoxanthine (nucleotide biosynthesis), choline (lipid processing), amino acids, taurine (thiol 
metabolism), and more indirectly to pyruvate, lactate and cholesterol. 
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The major sources of variation were identified based on t-tests and corrected for false discovery
rates (FDR) (Supplementary Tables S1 and S2). Unsupervised hierarchical cluster analysis again
showed distinct metabolomics differences in normal vs tumour tissue (Figure 2A,B).
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To gain further insights, the accumulation patterns of metabolites, which were significantly
different in our analyses, were plotted within established pathways. Examination of
nucleotide-associated metabolites indicated that differences in these were sufficient to discriminate
between lung SCC and normal tissues in PCA and HCA (Figure 5A,B). Further, three individual
metabolites exhibited AUC accuracies of >0.7 albeit with considerable variation (inosine, AUC= 0.848;
CI 0.68-0.957, xanthosine, AUC = 0.732; CI 0.529-0.895, deoxyinosine, AUC= 0.828; CI 0.656–0.949)
(Figure 5C).
Only slightly less prominent than nucleotides in our pathway analyses (Figure 3) was amino
acid metabolism. This can be linked to the well-characterised generated of ATP and reducing
equivalents that are required for growth and proliferation through the utilization of glucose to produce
lactate, possibly through the glycolytic pathway and the reductive carboxylation of glutamate [28].
Alternatively/additionally, this could reflect a contribution by oxidative phosphorylation (Figure 6).
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Metabolites 2019, 9, 47 7 of 14
Metabolites 2018, 8, x 7 of 15 
 
Only slightly less prominent than nucleotides in our pathway analyses (Figure 3) was amino 
acid metabolism. This can be linked to the well-characterised generated of ATP and reducing 
equivalents that are required for growth and proliferation through the utilization of glucose to 
produce lactate, possibly through the glycolytic pathway and the reductive carboxylation of 
glutamate [28]. Alternatively/additionally, this could reflect a contribution by oxidative 
phosphorylation (Figure 6). 
 
Figure 5. Altered nucleotide metabolism is a major feature of metabolism in lung SCC samples. 
Identified nucleotide metabolites for each sample were extracted from FIE-MS derived matrix and 
assessed by (A) principal component analyses and (B) hierarchical cluster analysis. (C) Area under 
the curve (AUC) and associated box and whisker plots of the main discriminatory nucleotide 
metabolites. 
Figure 5. Altered nucleotid metabolism is major feature of metabolism in lung SCC samples.
Identified nucleotide metabolites for each sampl were extracted from FIE-MS derived matrix and
a ssed by (A) principal compo ent analy es and (B) hierarchical cluster a al si . ( r the
curve (AUC) and associated box and whisker plots of the main discriminato y nucleotide metabolites.
Considering other changes in amino acid metabolism, important changes occurred in tryptophan
catabolism (Supplementary Figure S6). In one branch of the pathway, increased tryptophan synthesis
appeared to be driving the production of increased serotonin whilst melotonin levels were markedly
reduced in lung SCC. In another branch, the synthesis of anti-inflammatory kyneurine was reduced,
but there were increases in products, e.g., quiniolinate. Amino acid changes linked to the urea cycle
were also affected with the accumulation of ornithine and arginine being severely reduced in tumours
(Supplementary Figure S7). This inversely correlated with increased levels of urea and via ornithine
to the polyamine spermidine. Notably, the levels of other polyamines (putrescine) and spermidine
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were severely reduced, as was GABA. The reduction in arginine was accompanied by an accumulation
of creatine, but also by the absence of its less biologically-active derivative, creatinine. Another
important aspect of glutamine/glutamate metabolism is, with cysteine, to feed into thiol metabolism
(Supplementary Figure S8). In tumour samples, this apparently was linked to increases in glutathione,
glutathione derivatives, (lactoyl- glutathione and hydroxylmethytl glutathione), and also taurine.
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Pro-inflammatory events could be suggested by increases of the amino acid histidine through its
metabolite histamine (Supplementary Figure S9). Such changes were paralleled by increases in free
arachidonic acid, the precursor to eicosanoids such as prostaglandins. However, the levels of the core
prostaglandin H2 were reduced, which could reflect further processing into other prostaglandins or
sequestration of the increases of arachidonic acid into arachidonyl-CoA.
4. Discussion
Metabolomic approaches provide a comprehensive description of met bolism for a range of lung
cancer types, offering the possibility of improv d understa ding of their aetiology, diagnosis nd
treatment. A change in the cellular metabolism is required for tumo igenesis, and studies have sh wn
that cells n ed to generate an abundant amount of ATP fo e ergy, along with de novo synthesis of
nucl otid s, lipids and proteins for fast proliferatio [29]. Foundational metabolomic studies on lung
ca c r established alterations in the Krebs cycle, pyruvate carboxylati n and lactate biochemistry,
aligning with the perturbed bioenergy metabol sm, which is a hallmark f cancer. Others soon
considered differe ces between lung AD and SCC [30]. Such studi s focused on a small number of
patient samples, but a recent large metabolomic study based on 136 lung tissue samples has compared
tumours and histologic lly norm l tissue for each patient. Our study was smaller, with only samples
from eight patients, pai ed with histolog cally normal sa ples d focused on SCC. How ver, whilst
it confirmed many of the f atures of the M reno et al. study by defining some new distinctive changes,
it also demonstrated the value of FIE-MS i m tabolomic stud es of LC biopsies [31].
A ra ge of metabolo ic detection technologies have been employed in LC biopsy studies.
These include nuclear magne ic resonance (NMR) [12], gas-chromatography MS (GC-MS) [31,32] and
ultra-performance liquid chromatography (UPLC) linked to an Orbitrap Q Ex ctiv Plus or lin r trap
quadrupole mass spectrometers. FIE-MS metabolomics offers the possibility of fast diagnoses, due to
its high-throu hput screening ability to apture a wide range of m tabolites leading to reduced analysis
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times. Further, beyond a metabolite fingerprinting tool, when coupled with high resolution MS, FIE
can provide some comprehensive descriptions of metabolites in a given sample to yield new insights.
In this context, our FIE-MS-based analyses yielded large numbers of identified metabolites which could
be identified based on high-resolution (3 ppm) data and ionisation patterns (Supplementary Tables S1
and S2), which significantly differed between SCC and histologically normal tissue. Further, analyses
indicated changes in SCC which had been previously described in the literature (Supplementary
Figure S3), but with novel features.
Warburg considered that in tumour cells, mitochondrial oxidative phosphorylation was
permanently defective, making aerobic glycolysis the alternative and the main resource of energy for
tumour cells [33]. For example, K-RAS activation in NSCLC cells was metabolically linked with the
decoupling of glycolysis and TCA metabolism, with glutamine supplying increased carbon to drive
the TCA cycle [34]. Although the genetic bases of our SCC samples were not defined, our results agree
with such studies with the predominance of aerobic glycolysis, fed by glutamine/glutamate to feed
the generation of ATP and reducing equivalents (Figure 6).
Mapping the significantly different metabolites on to KEGG metabolism indicated that alterations
in nucleotide metabolism were predominant in lung SCC samples (Figure 3; Supplementary Figures
S1 and S2). These observations agreed with the AD and SCC tumours, where nucleotide metabolism
was suggested for therapeutic interventions and biomarkers (Moreau et al., 2018). The Moreau et al.
study defined the top five nucleotides and metabolites which discriminated between AD and SCC
tissue as indicated by AUC analysis. Most metabolites linked with SCC, but none of those with AD
metabolites was also observed in our data with good AUC scores (Figure 6). Consistent with this,
we observed increases in glycine, representing a major node in our network analysis (Figure 5). Glycine
is a major source of methyl groups for the one-carbon pools, and is required for the biosynthesis of
purines [35]. Glycine consumption and the expression of enzymes in the mitochondrial biosynthetic
pathway correlate with the proliferation rate of cancer cells [36]. Glycine decarboxylase (GLDC) is
crucial for tumour initiating cells in NSCLC, and was associated with pyrimidine metabolism to
support cancer cell proliferation [37].
Another prominent change in lung SCC cells was the increases in the accumulation of most amino
acids (Figure 3), represented by alanine and valine in our network analysis (Figure 4). One important
regulatory node appears to be arginine/ornithine metabolism, which is important in supplying
nitrogenous compounds to proliferating cancer cells [38]. Amongst our significant amino acid changes
that could be linked to this urea cycle was a major reduction in both ornithine and arginine in SCC
samples. This could reflect a rewiring of the metabolism toward urea and/or the production of NO
via nitric oxide synthases with the co-production of citrulline (Supplementary Figure S7), and would
support with a role of NO in tumour progression [39]. Arginine also appeared to be feeding into the
production of creatinine, which apparently accumulated to the detriment of its catabolites, particularly
creatinine (Supplementary Figure S7). Creatine forms part of an ATP buffering system comprised of
the phosphocreatine (PCr)-creatine kinase (CK) shuttle, and has been linked to the Warburg effect and
cancer progression [40].
Higher creatine levels have been seen in NSCLC when compared with normal tissue [41] and in
SCLC primary tumours and cell cultures [42]. Lung AD and SCC tissues had lower CK activity, which
accords with our elevated creatine levels [43], and was linked to a poor prognosis in LC patients [44].
Considering ornithine as a route to the production of polyamines, with the exception of spermidine,
this was reduced. This differed from lung AD where spermine levels were elevated [45]. Also striking
was a reduction in GABA, which is negative regulator of cell proliferation [46]. This agrees with the
methylation and reduced expression of the GABA receptor GABBR2 in LC. Further, NSCLC patient
with higher GABBR2 expression had a better prognosis, possibly through links to EGFR signalling [47].
In the case of tryptophan metabolism, the effects appear to be seen in the accumulation of serotonin
(5-hydroxytryptamine, 5-HT), to the detriment of melatonin. Serotonin has been suggested to be a
growth factor in several cancers including SCLC, although not previously in lung SCC [48]. Serotonin
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has also been linked to angiogenesis and metastasis. In solid tumours, platelet aggregation can release
serotonin, which may constitute one of the mechanisms of tumour progression and angiogenesis,
and could result in higher serotonin levels in the blood [49].
Taurine also formed a node in our network model (Figure 4); this was indicative of wider effect
on thiol metabolism (Supplementary Figure S8). Cysteine metabolism partly fed into increases in
hypotaurine and taurine in SCC samples. This was unlike decreases observed in taurine in the
lung adenocarcinoma cell line A549, which allowed us to conclude that taurine can inhibit cell
proliferation [50], or that levels of taurine are reduced in patients with breast cancer [51]. Additionally,
cysteine fed into glutathione production excess of the latter promotes tumour progression, where high
levels are correlated with increased metastasis [52]. Glutathione also seemed to be feeding into the
glyoxalase system in an attempt to remove methylglyoxal as a side product of anaerobic glycolysis.
Increases in methylglyoxal lead to genomic damage [53]. The formation of S-lactoyl glutathione is
catalysed by glyoxalase 1 (Glo1) and under-expression can promote tumour growth [54]. Perhaps
counter-intuitively, over expression of Glo1 is a biomarker for tumour growth, but this is likely to
reflect high-glycolytic activity, as we observed in SCC tissues [55].
Other well-established features were also observed in our lung SCC metabolomes. Choline is a
marker for lipid processing and was key network node in our analyses (Figure 4). Abnormalities in
choline metabolism are emerging as a metabolic hallmark of oncogenesis and tumour progression [50].
Increases in cholesterol are components of increased lipid biosynthesis to support the production
of membranes [56]. Cholesterols are essential to the formation of lipid rafts and are platforms of
oncogenic activation of PI3K-Akt-mTORC1 [57] or EGRF [58], with the efficacy of tyrosine kinase
inhibitors being affected by EGFR location to lipid rafts. Key metabolites of the mevalonate pathway
accumulated in SCC tumours, as well-established in cancer tissues, to feed into, amongst other things,
cholesterol [59].
Other notable changes included increases in a range of vitamins and cofactors that are indicative
of increased cellular metabolism, some of which have not been previously reported in lung SCC tissue.
Thus, vitamin B1 (thiamine) plays an essential role in key enzyme of the pentose phosphate pathway
and amino acid catabolism [60]. Increases in B1, linked to increased expression of the transporter
(THTR2), have been reported in breast cancer, and chemotherapeutic drugs such as 5-fluorouracil
(5-FU) result in a thiamine-deficient state [61,62]. The role of thiamine appears to be dose dependent,
with low doses serving to promote, but with high doses suppressing proliferation [63]. Vitamin
B2 (riboflavin) is a cofactor for methylenetetrahydrofolate reductase (MTHFR), which is important
for nucleotide production. Treatment with high dose riboflavin could enhance lung carcinogenesis,
but increases have not been linked to SCC tumours [64].
Pyridoxal 5’-phosphate (PLP), the active form of vitamin B6, works as cofactor in numerous
enzymatic reactions; it behaves as antioxidant molecule [65]. Unlike other cofactors, deficiencies in
PLP are seen in cancer tissues including lung cancer [66,67], and this may be linked to antioxidant and
maintenance of genome integrity [65]. This may reflect the role of PLP as a cofactor for SHMT, which
catalyzes the reversible conversion of serine and tetrahydrofolate to feed into nucleotide biosynthesis.
Thus, reduced PLP links with corresponding increases in nucleotide and serine production.
Perturbation of the inflammatory response is a cancer hallmark, but our study yielded equivocal
results. Histidine feeding through to histamine could be linked to pro-inflammatory events,
but arachidonic acid levels and those of the central intermediate eiconsanoid biosynthesis were
suppressed. The kynurenine pathway can be involved in immune suppression, and can contribute to
immune privilege in cancer microenviroments [68]. However, this pathway was not significant in SCC
tumours, with any changes possibly feeding into NAD+ biosynthesis (Supplementary Figure S6).
5. Conclusions
Our analyses show that untargeted FIE- MS represents an appropriate approach to develop an
understanding of the metabolic process of growth and proliferation in SCC. This is demonstrated
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through our observation of well-characterised biochemical pathways in lung cancer pathways.
Our findings give a general idea of the metabolites that are in the metabolic pathways of nucleotide
metabolism, amino acid metabolism and energy metabolism, which are important pathways that
provide the necessary supplies for tumour growth and proliferation. The ability of FIE-MS to indicate
novel aspects was also highlighted in our work. We demonstrate some features in SCC samples which
have yet to be described in this tissue type, including changes in vitamin cofactors, serotonin and a
reduction in GABA (a putative tumour suppressor). Given the high throughput potential of FIE-MS,
it is possible to apply such approaches in strategies focusing on personalised medicine.
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